XML 115 R101.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Information (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Apr. 07, 2020
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Selected Quarterly Financial Information [Line Items]                        
Total revenues   $ 7,421 $ 6,577 $ 5,143 $ 5,548 $ 5,879 $ 5,604 $ 5,685 $ 5,281 $ 24,689 $ 22,449 $ 22,127
Gross profit on product sales   5,930 5,352 4,003 4,498 4,113 4,481 4,607 4,243      
Net income   1,544 353 (3,346) 1,538 2,689 (1,168) 1,875 1,968 89 5,364 5,460
Net income attributable to Gilead   $ 1,551 $ 360 $ (3,339) $ 1,551 $ 2,696 $ (1,165) $ 1,880 $ 1,975 $ 123 $ 5,386 $ 5,455
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)   $ 1.24 $ 0.29 $ (2.66) $ 1.23 $ 2.13 $ (0.92) $ 1.48 $ 1.55 $ 0.10 $ 4.24 $ 4.20
Net income per share attributable to Gilead common stockholders - diluted (usd per share)   1.23 0.29 (2.66) $ 1.22 $ 2.12 (0.92) $ 1.47 $ 1.54 $ 0.10 $ 4.22 $ 4.17
Acquired in-process research and development expenses                   $ 5,856 $ 4,251 $ 0
Unrealized loss on investment of equity securities                   1,700    
Income tax expense (benefit)                   1,580 (204) 2,339
Unrealized gain on investment of equity securities                     1,200  
Impairment charge related to IPR&D intangible asset           $ 800       0 800 820
Inventory write-downs                     649 572
Favorable EPS Impact                        
Selected Quarterly Financial Information [Line Items]                        
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)           $ 0.83            
Net income per share attributable to Gilead common stockholders - diluted (usd per share)           $ 0.81            
Inventory Write-downs for Excess Raw Materials                        
Selected Quarterly Financial Information [Line Items]                        
Inventory write-downs           $ 500         547 440
Intangible Asset Transfer                        
Selected Quarterly Financial Information [Line Items]                        
Unrealized gain on investment of equity securities           929            
Intangible Asset Transfer                        
Selected Quarterly Financial Information [Line Items]                        
Income tax expense (benefit)           $ 1,200         (1,200) $ 588
Immunomedics, Inc.                        
Selected Quarterly Financial Information [Line Items]                        
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)   0.49                    
Net income per share attributable to Gilead common stockholders - diluted (usd per share)   $ 0.49                    
Acquisition-related expenses   $ 615               39    
Arcus, Pionyr, Tango and Tizona                        
Selected Quarterly Financial Information [Line Items]                        
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)     0.82                  
Net income per share attributable to Gilead common stockholders - diluted (usd per share)     $ 0.82                  
Acquired in-process research and development expenses     $ 1,000                  
Galapagos subscription agreement | Galapagos                        
Selected Quarterly Financial Information [Line Items]                        
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)   $ 0.50 $ 0.78       2.40          
Net income per share attributable to Gilead common stockholders - diluted (usd per share)   $ 0.50 $ 0.78       $ 2.40          
Acquired in-process research and development expenses             $ 3,920       $ 3,920  
Unrealized loss on investment of equity securities   $ 628 $ 983             $ 1,830    
Forty Seven, Inc.                        
Selected Quarterly Financial Information [Line Items]                        
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)       3.58                
Net income per share attributable to Gilead common stockholders - diluted (usd per share)       $ 3.58                
Acquired in-process research and development expenses $ 4,500     $ 4,500